BNET Industries

Market Cap:$8.6M
Last Fiscal Year Sales:$14.7M
  • Public
  • US
Dow Jones Description

Neurobiological Technologies, Inc. is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug with multiple mechanisms of action that is specifically designed to double the time period that patients can be treated after the onset of a stroke. NTI also has the right to receive royalty payments from sales of Namenda(R) (memantine HCL), an approved drug marketed for Alzheimer's disease, and the right to receive payments from the development and marketing of XERECEPT(R) (corticorelin acetate injection), an investigational drug in Phase 3 clinical development for swelling associated with brain tumors. Additionally, NTI has rights to two compounds in early-stage development for Alzheimer's and Huntington's diseases.

President & CEO
Paul E. Freiman
Number of Employees 32
Contact Information

2000 Powell Street

Suite 800

Emeryville, California 94608

www.ntii.com

(510) 595-6000

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Recent Events

  • Neurobiological Technologies, Inc. NTII Announces Extraordinary Dividend of $0.18 per Share Company also Announces Timing...

    11/23/09 - Stock Split / Dividend - View Story

  • Neurobiological Technologies liquidation gets stockholders OK

    10/28/09 - Board Member - Leaving - View Story

  • Neurobiological Technologies' Stockholders Approve Plan Of Liquidation And Dissolution - Quick Facts

    10/28/09 - Stock Split / Dividend - View Story

  • UPDATE 1-Neurobiological board approves liquidation plan

    8/31/09 - Financial Announcement - View Story

News & Analysis

neurobiological technologies inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Paul E. Freiman President & CEO
Matthew Loar Vice President and Chief Financial Officer
Warren W. Wasiewski Vice President, Chief Medical Officer
David E. Levy Vice President, Clinical Development
Karl G. Trass Vice President, Regulatory Affairs & Quality Assurance
Stephen J. Petti Vice President
David C. Chou Director, Chemistry, Nfg & Controls
Stephen C. Ferruolo Secretary

Board of Directors

Name (plus bio) Position
Abraham E. Cohen Chairman
Abraham Sofaer Board of Directors
Enoch Callaway Board of Directors
F. Van Kasper Board of Directors
John B. Stuppin Board of Directors
Theodore L. Eliot Board of Directors
William A. Fletcher Board of Directors

Organization Position Status
Syntex Corporation Chief Executive Officer Current
Neurobiological Technologies, Inc. President & CEO Current
Scigen Ltd Leading Independant Director Current
Penwest Pharmaceuticals, Co. Chairman Current
Omware, Inc. Director Current
Phytos Inc Director Current
NovaBay Pharmaceuticals, Inc. Board of Directors Current
Scigen Ltd Board of Directors Current
NeoPharm, Inc. Board of Directors Current
Novacal Pharmaceuticals, Inc. Board of Directors Current
Calypte Biomedical Corporation Board of Directors Current
Neurobiological Technologies, Inc. Board of Directors Current
Syntex Corporation chairman Former
Penwest Pharmaceuticals, Co. Board of Directors Former
Calypte Biomedical Corporation Director Former
Nti, Inc. Director Former
Fordham University B.S. Degree In Pharmacy Former

Organization Position Status
Osteologix, Inc. Chief Financial Officer Current
Neurobiological Technologies, Inc. Vice President and Chief Financial Officer Current
Genelabs Technologies, Inc. CFO Former
PricewaterhouseCoopers Former
University of California, Berkeley B.A. in Legal Studies Former

Organization Position Status
Neurobiological Technologies, Inc. Vice President, Chief Medical Officer Current
American Heart Association, Inc. Current
Pediatric Neurology Associates Consultant Former
Lancaster General Hospital Chairman Former
The State University of New York Doctorate of Medicine Former
The State University of New York Masters of Science In Biochemistry Former
Rutgers College Bachelor of Arts In Biology Cum Laude Former

Organization Position Status
Neurobiological Technologies, Inc. Vice President, Clinical Development Current
DOV Pharmaceutical, Inc. senior director Former
Harvard Medical School doctor of medicine degree Former
Harvard College B.A. in chemistry and physics Former

Organization Position Status
Neurobiological Technologies, Inc. Vice President, Regulatory Affairs & Quality Assurance Current
Genentech, Inc. Senior Manager for Regulatory Affairs Former
Indiana University bachelor's degree in chemistry Former

Organization Position Status
Neurobiological Technologies, Inc. Vice President Current
Nti, Inc. Vice President of Product Development Former
Dominican College B.S.N. degree in nursing education Former

Organization Position Status
Neurobiological Technologies, Inc. Director, Chemistry, Nfg & Controls Current

Organization Position Status
Neurobiological Technologies, Inc. Secretary Current

Abraham E. Cohen has been a director of NTI since March 1993 and has been chairman of the board since August 1993. From 1982 to 1992, Mr. Cohen served as Senior Vice President of Merck & Co. and from 1977 to 1988 as President of the Merck Sharp & Dohme International Division ("MSDI"). While at Merck, he played a key role in the development of Merck's international business, initially in Asia, then in Europe and, subsequently, as President of MSDI, which manufactures and markets human health products outside the United States. Since his retirement from Merck and MSDI in January 1992, Mr. Cohen has been active as an international business consultant. He was a director of Agouron Pharmaceuticals, Inc. until its merger with Warner-Lambert Company. He is currently Chairman and President of Kramex Corporation and serves as a director of four other public companies: Akzo Nobel N.V., Chugai Pharmaceutical Co., Teva Pharmaceutical Industries, Ltd. and Vasomedical, Inc.

Organization Position Status
Neurobiological Technologies, Inc. Chairman Current
Neurobiological Technologies, Inc. Chairman Current
Merck & Co. Inc. Senior Vice President Former
Agouron Pharmaceuticals, Inc. Director Former
Nti, Inc. Director Former

Organization Position Status
Plc Diagnostics Founder & Chairman of The Board Current
Neurobiological Technologies, Inc. Board of Directors Current
Mlt Research Limited Director Current
Nti, Inc. Director Current
Gen-Probe Inc. Board of Directors Current
Plc Diagnostics Board of Directors Current
Columbia University Law School Professor Former
United States Department of State Senior Legal Adviser Former
American Arbitration Association qualified arbitrator Former
New York University L.L.B. degree Former
New York University School of Law L.L.B. Former
Yeshiva University B.A. In History Former

Is a founder of the Company and served as a director of the Company from September 1987 to February 2008. Dr. Callaway previously served as chairman of the Board of the Company from September 1987 to November 1990, as co-chairman of the Board of the Company from November 1990 until August 1993, as Vice President of the Company from September 1988 until August 1993 and as Secretary of the Company from September 1988 until September 1991. Dr. Callaway has been Emeritus Professor of Psychiatry at the University of California, San Francisco since 1986, where he also served as Director of Research at the Langley Porter Psychiatric Institute from 1959 to 1986. Dr. Callaway was Staff Psychiatrist, SFVAMC, 1996-1997. He is a member of the Institutional Review Board for SAM Technologies, Inc and Abratech, Inc. He continues to practice clinical psychopharmacology part time.

Organization Position Status
Neurobiological Technologies, Inc. Board of Directors Current
Nti, Inc. founder Former
Columbia University M.D. Former

F. Van Kasper joined the NTI board of directors in January 2004 and serves as chairman of the company's audit committee. Prior to his retirement in March 2003, Mr. Kasper served as Chairman of Wells Fargo Securities, the institutional brokerage and investment bank for Wells Fargo and Company. Mr. Kasper entered the brokerage business in 1964 with Merrill Lynch and in 1978 co-founded Van Kasper and Company, a regional investment bank. As Chairman and CEO of Van Kasper, he guided its growth from a handful of employees to one with over 350 employees in 15 offices in 4 states when the firm was sold in 1999. During his investment career, Mr. Kasper was elected as a Governor of the National Association of Securities Dealers (NASD) and as a Director and Vice Chairman of the Securities Industry Association (SIA). Mr. Kasper is active in the Bay Area non-profit community, most recently as Chairman of the Investment Committee for the University of California San Francisco Foundation (UCSF) and serves as Chairman Emeritus for San Francisco's Exploratorium Museum.

Organization Position Status
Neurobiological Technologies, Inc. Board of Directors Current

Organization Position Status
Fiberstars, Inc. chairman Current
Fiberstars, Inc. Board of Directors Current
Neurobiological Technologies, Inc. Board of Directors Current
Nti, Inc. founder Former

Theodore L. Eliot, Jr. has served as a director of NTI since August 1992. He joined the company in 1988 as Vice President. Mr. Eliot retired from the United States Department of State in 1978, after a 30-year career in which he held senior posts in Washington and was Ambassador to Afghanistan. He was Dean of the Fletcher School of Law and Diplomacy from 1978 to 1985 and a director of Raytheon Co. from 1983 to 1998. He is currently a director of Fiberstars, Inc. and of several non-profit organizations. Mr. Eliot holds B.A. and M.P.A. degrees from Harvard University.

Organization Position Status
Neurobiological Technologies, Inc. Board of Directors Current

William Fletcher was President & CEO of Teva?s North American activities from 1985 until the end of 2004, when he became Chairman ? North America. Teva, one of Israel?s largest industrial companies, holds the leading position in the global generic drug industry and commands a significant presence in the specialty neurology market. Mr. Fletcher served as Vice President, Sales and Marketing of the Pennsylvania based Lemmon Company (1980 to 1983) and then as President (1983-1985) following the company?s acquisition by Teva and WR Grace. Prior to 1980, Mr. Fletcher was Business Development Manager and International Marketing Manager of Synthelabo, a pharmaceutical subsidiary of L?Oreal in Paris. From 1970 to 1977 he served in various international sales and marketing positions for Hoffman-LaRoche. Mr. Fletcher graduated in International Marketing from Woolwich Polytechnic, London (now Greenwich University) in 1969. He serves as a Board Member for several Teva subsidiary companies in North America and Europe, and is a Director of Sportwall International Inc., a growth company in the interactive fitness industry.

Organization Position Status
Sportwall International, Inc. Director Current
Neurobiological Technologies, Inc. Board of Directors Current
W.R. Grace & Company Former
Greenwich University Former
advertisement
     NTII $0.32 +0.06 (23.03% )
Average Volume 241,452
Shares Outstanding 27.02M
Market Cap 8.6M
Year High 1.05
Year Low 0.182
Earnings Per Share 0.42
P/E Ratio 0.76
Dividend N/A
Yield N/A
advertisement